15
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

High proviral load of human T-lymphotropic virus type I in patients with myelodysplastic syndrome carrying HLA-A26

, , , , , , , , , , & show all
Pages 1400-1403 | Received 20 Jun 2005, Accepted 02 Jan 2006, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Hirosaka Inoue, Kakushi Matsushita, Naomichi Arima, Heiichiro Hamada, Kimiharu Uozumi, Atsuo Ozaki, Masaki Akimoto, Hideaki Kawada, Toshimasa Kukita, Makoto Yoshimitsu, Tadashi Matsumoto & Chuwa Tei. (2008) High prevalence of human T-lymphotropic virus type I carriers among patients with myelodysplastic syndrome refractory anemia with excess of blasts (RAEB), RAEB in transformation and acute promyelocytic leukemia. Leukemia & Lymphoma 49:2, pages 315-321.
Read now

Articles from other publishers (1)

Masako IwanagaToshiki WatanabeAtae UtsunomiyaAkihiko OkayamaKaoru UchimaruKi-Ryang KohMasao OgataHiroshi KikuchiYasuko SagaraKimiharu UozumiManabu MochizukiKunihiro TsukasakiYoshio SaburiMasaomi YamamuraJunji TanakaYukiyoshi MoriuchiShigeo HinoShimeru Kamihira & Kazunari Yamaguchi. (2010) Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 116:8, pages 1211-1219.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.